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Background: The purpose of this study was to examine the prevalence of sleep problems in a community-based
sample of patients with Parkinson’s disease (PD) in Norway, and their associated factors.
Methods: 176 consecutive PD outpatients (41% females) were included in a study of non-motor symptoms,
including sleep problems. All participants responded to the Parkinson’s Disease Sleep Scale (PDSS), where an overall
score below 82 or a score below 5 on a sub-item indicate possible sleep problem. Factors associated with sleep
were also investigated, with special emphasis on severity of PD, fatigue, mental health and restless legs syndrome
(RLS).
Results: The mean age was 68.5 years (range 35–90); the mean Hoehn and Yahr stage was 2.11 (SD 0.86), and the
mean UPDRS part III was 22.3 (SD 11.7). Sleep problems were common among PD patients. While only 17% of the
sample had an overall score below 82 on the PDSS, 70% of the patients had a score below 5 on one item. There
was no significant association between PD severity and any of the sleep items in the PDSS; whereas fatigue, mental
health problems, and RLS were associated with PDSS score.
Conclusions: The current findings call for increased awareness of sleep problems in PD patients, especially focusing
on the association with mental health problems, fatigue and RLS.
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Parkinson’s Disease (PD) is the second most common
neurodegenerative disorder, and primarily affects the
elderly: while approximately 1% of people aged 65 to 69
suffer from PD, the prevalence increases to nearly 5%
among people aged 80 to 84 [1]. PD is characterized not
only by movement abnormalities, but also by non-motor
symptoms such as fatigue, pain, and sleep problems [2-
4]. Sleep problems are common; community studies
have reported that about 60% of PD patients had a sleep
disorder compared to 33% of the controls [5]. Common
sleep problems include insomnia symptoms (difficulty
initiating and maintaining sleep), excessive daytime som-
nolence, and REM sleep behaviour disorder (RBD)[6].
However, even though this is a common problem, the
diagnostic accuracy of sleep problems in PD patients is
only 60% [7].* Correspondence: elisabeth.svensson@dce.au.dk
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reproduction in any medium, provided the orIt has been recommended that assessment of PD
should also include a disease-specific instrument for
measurement of sleep disturbances [8]. The Parkinson’s
Disease Sleep Scale (PDSS) was developed on this back-
ground and also because the generic sleep assessment
scales do not systematically address and quantify the
most common sleep problems in PD patients [9]. As
such, this bedside tool can provide an indication for
treatment of the sleep problems commonly accompany-
ing PD.
Sleep and its associated factors in PD patients have
been examined in several studies [6,10], but the predict-
ive factors are found to vary and the results must be
considered contradictory. One example is the relation-
ship between sleep disturbance and fatigue: although it
has been shown that sleep problems and fatigue fre-
quently co-occur in PD, it has also been suggested that
they should be regarded as distinct symptoms that must
be understood and managed separately [11]. Another
and more consistent relationship is that betweenal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of restless legs syndrome (RLS) are commonly reported
by PD-patients, and such symptoms have also been asso-
ciated with sleep problems [15]. Finally, there are reports
of an association between PD severity and sleep pro-
blems [9] however, these results are also inconsistent [5].
The purpose of this study was to examine self-
reported sleep problems among PD patients in a
community-based sample from Norway. Associated fac-
tors with sleep problems were also investigated, with
special emphasis on disease stage, age and gender, men-
tal health, fatigue and restless legs syndrome.
Methods
Material
All PD-patients living in the eastern part of Akershus
county, Norway (320 000 inhabitants), were defined as
the target population. Detailed information about the
inclusion has been published previously (see [3]). In
short, a total of 413 PD patients were identified in the
out-patient registry at the Department of Neurology,
Akershus University Hospital; the only Neurological De-
partment in the county. Only 243 patients fulfilled the
inclusion criteria: PD diagnosis according to published
diagnostic criteria [16], as well as mentally (Mini Mental
State Examination, with a score ≥ 23 [17]) and physically
able to complete interviews, self-report questionnaires
and clinical examinations lasting for at least two hours.
The data collection was organised as part of a yearly
follow-up consultation. If patients did not want to par-
ticipate, the regular consultations were conducted as
scheduled. Due to financial restraints the inclusion
period had to be shortened before the entire cohort was
examined. The last forty-one eligible patients were
therefore not invited to participate. Thus, 202 eligible
patients were invited, 17 rejected, six did not answer,
and three did not show up. In total, 176 eligible patients
were included consecutively until the end of the inclu-
sion-period, yielding a response rate of 87% (176/202).
All patients were on dopaminergic medications. In
addition, in total 8.5% were on treatment with anti-
depressants/anticonvulsants with the intent of anti-
depressive or pain-relieving effects [3].
Instruments
Through a structured interview, conducted as part of the
clinical examination, information on PD, such as date of
first symptom, date of diagnosis, and date of initiating
therapy, were collected and recorded. After the clinical
examination, patients were asked to complete a self-report
questionnaire, which consisted of, among others, demo-
graphic information, and well-established instruments for
assessment of sleep disturbances, fatigue, mental health
problems and restless legs syndrome.Staging of the disease was based upon the findings of
the clinical examination and in accordance with present
standards (Hoehn and Yahr Staging [18] and Unified
Parkinson’s Disease Rating Scale, UPDRS [19]). Cogni-
tive functioning was assessed by the Mini Mental State
Examination (MMSE) [17]. All patients suffering from
motor fluctuations (the fluctuating stage of the disease =
on/off-periods) were examined during the on-period.
Sleep problems were assessed by the Parkinson’s dis-
ease Sleep Scale (PDSS)[9]. The PDSS include 15 ques-
tions addressing the following 8 items: Overall quality of
night’s sleep (question 1), sleep onset and maintenance
insomnia (questions 2 and 3), nocturnal restlessness
(questions 4 and 5), nocturnal psychosis (questions 6
and 7), nocturia (questions 8 and 9), nocturnal motor
symptoms (questions 10–13), sleep refreshment (ques-
tion 14) and daytime dozing (question 15). The response
format is a 0–10 cm visual analogue scale, where 0 indi-
cates that a symptom is severe and always experienced,
while 10 means being free of symptoms. The score on
each item is summarised into a total score giving a range
of scores from 0 (most severe) to 150 (free of symp-
toms). Based on comparisons with polysomnography
and other sleep questionnaires such as the Epworth
Sleep scale, the PDSS appears to be a reliable tool to
evaluate sleep characteristics in PD patients. [20] It is
suggested that individuals obtaining an overall score
below 82 or a score under 5 on any sub- item on the
PDSS should be referred for formal sleep studies [21,22].
Fatigue was assessed by the Norwegian version of the
Fatigue Questionnaire FQ [23,24]. The FQ includes 11
items, and previous factor analyses support a two-factor
solution; mental and physical fatigue. The sum score of
responses to all 11 items is designated total fatigue, with
minimum/maximum scores of 0/33. The FQ was origin-
ally validated in primary care, and has demonstrated
good face- and discriminant validity as well as good and
stable psychometric properties across populations [23].
Reference data on fatigue levels from the Norwegian
general population exists [24].
Mental health was assessed by the mental health (MH)
subscale (5 items) of the Short Form 36 (SF-36) [25].
The SF-36 has been validated in the general Norwegian
population [26]. Each item of the mental health subscale
is scored on a 6 point category scale. The scores on all
items are summed and transformed into a 0–100 scale
(0 = poorest possible health state, 100 = best possible
health state). A score below 50 is thought to indicate
poor mental health.
Restless legs syndrome was assessed in a clinical inter-
view by an experienced neurologist, based on the 4 es-
sential criteria put forward by the International Restless
Legs Syndrome Study Group[27], resulting in a dichot-
omous score (no/yes).
Table 1 Sleep problems, by PDSS items, for 176 patients
with Parkinson’s disease
mean (± SD) % scoring <5
Item 1: Quality of nights sleep 6.0 (2.9) 37
Item 2: Sleep onset and
maintenance insomnia
7.0 (2.5) 25
Item 3: Nocturnal restlessness 5.7 (2.8) 36
Item 4: Nocturnal psychosis 8.2 (2.0) 8
Item 5: Nocturia 5.8 (2.0) 26
Item 6: Nocturnal motor symptoms 7.5 (2.0) 11
Item 7: Sleep refreshment 6.1 (3.1) 35
Item 8: Daytime dozing 7.1 (3.3) 28
Total 102.8 (23.3) 70
Table 2 Demographic and clinical factors associated with
sleep problems (assessed by total PDSS score) from a
block-wise multiple regression analyses in 176
Norwegian PD patients
Block one Block two Block three
Variable Beta p-value Beta p-value Beta p-value
Age (yrs) 0.12 0.1 0.14 0.07 0.01 0.1
Gender −0.04 0.6 -.05 0.5 0.07 0.2
Disease duration (yrs) −0.12 0.13 −0.09 0.2
UPDRS sum part III −0.15 0.07 −0.05 0.5
Mental health (SF-36) 0.36 <0.001
Fatigue (FQ) −0.17 0.02
Restless legs syndrome −0.34 <0.001
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sent was obtained from all respondents.
Statistical methods
Descriptive statistics for sleep problems, clinical and
demographic variables were calculated. Further charac-
teristics of PDSS were investigated, such as proportion
of patients scoring under 82 points. The entire UPDRS
was conducted, but only results from stage III will be
reported. To analyse possible associations between sleep
problems and characteristics of PD, demographic status,
fatigue, mental health and co-morbidities, linear multiple
regression was used. Crude bivariate analyses were con-
ducted (data not shown). A stepwise approach was con-
ducted; block one including demographic factors (age
and gender), block two adding disease characteristics
(disease duration and UPDRS part III) and block three
adding other possible explanatory factors (fatigue, men-
tal health, restless legs syndrome).
A significance level of 0.05 was chosen. Analyses were
performed using STATA version 11.
Results
Sample characteristics
Of the 176 patients examined, 41% were women, and
the mean age was 68.5 years (SD 8.8 years). The mean
UPDRS part III was 22.3 (SD11.7). The mean Hoehn
and Yahr stage was 2.11 (SD 0.86), the median is 2, and
the interquartile range is 1. More specifically, 39.2% are
in stage 1, 38.1% are in stage 2, 14.8% are in stage 3 and
8% in stage 4 of Hoehn and Yahr. For patients suffering
from motor fluctuations (the fluctuating stage of the dis-
ease = on-/off-periods), all were examined during the on-
period. The mean duration of PD was 7.5 years (SD 5.3)
and the mean MMSE was 28 (range 23–30). The mean
mental health SF-36 score was 72.3 (SD 18.8), and the
mean total fatigue score was 15 (SD 5.0). RLS was
reported by 27% of the patients, and was significantly
more common in patients with Hoehn and Yahr stage
1–2 (26%), compared to those with stage 3–4 (10%).
Sleep problems in PD patients
The overall mean total PDSS score was 102.8 (SD 23.3),
and 17% (N= 32) of the patients had a total PDSS score
under 82. A more detailed examination of the PDSS
sub-scales and proportion of patients scoring below 5
are shown in Table 1). In total, 70% had a total score
under 5 on one or more items of the PDSS. There were
no significant differences in Hoehn and Yahr stage 1–2
vs 3–4 for any of the PDSS items.
Factors associated with sleep problems are shown in
Table 2. Only total fatigue score, RLS and mental health
problems were factors associated with PDSS score.The adjusted R2 for the final model was 0.39.
Discussion
Sleep problems were common among the PD patients
examined. No association was found between PD sever-
ity and sleep problems in this community-based popula-
tion of medicated patients, of whom 71% had a mild
disease. In contrast in this group, the sleep problems
were related to mental health problems, fatigue and
RLS.
The prevalence of sleep problems among PD patients
depends on the population examined and the definition
of sleep problems (i.e. the assessment method). In Nor-
way, the prevalence of PD is about 111 per 100.000 inha-
bitants [28], suggesting about 355 patients in our
recruitment area. Thus, our initial population of 345 was
probably close to all cases in the catchment area. The re-
sponse rate was 87%. We therefore consider the present
study to have good external validity for a community-
based study, although it was conducted at a single insti-
tution. On the other hand, although this study might be
representative for the Norwegian population, the results
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large. For sleep assessment use, the PDSS was used. The
clinimetric properties of the instrument are valid and
widely used. However, there are some limitations of the
instrument, as it does not measure some of the sleep
disorders, such as REM behaviours disorder, and others
may be underdiagnosed, such as diurnal somnolence.
A limitation of the generalizability is that the study
does not address sleep problems in PD patients with
dementia or in patients otherwise unable to utilize self-
report instruments for data collection. Another limita-
tion of the study is that there is no control population,
and since PDSS is a disease-specific scale, there are no
Norwegian norm data available. Furthermore, all
patients are examined when in medicated state, and we
did not further specifically explore the relationship be-
tween the PD medications and sleep. The treatment of
the disease may affect the sleep disorder; low doses of
dopamine agonists has been shown to promote sleep,
whereas high doses both during the day and in the even-
ing may lead to increased nocturnal awakenings,
reduced slow-wave sleep, and decreased sleep continuity
[29].
In the current study, only 17% of the patients had a
PDSS score under 82, which is the recommended clin-
ical cut-off for the PDSS. However, when examining the
specific PDSS sub-scales, over a third of the sample
reported poor quality of sleep, nocturnal restlessness,
and poor sleep refreshment. In total, 70% had a total
score under 5 on one or more items of the PDSS. Con-
sequently, several of these patients are candidates for re-
ferral to further formal sleep tests according to the
recommendations for the use of PDSS. The availability
of objective sleep studies for verification and established
treatment options for sleep problems should prompt
physicians to refer PD patients with specific sleep com-
plaints to PSG and sleep apnoea studies. Still, in Norway
there is a strikingly low rate of PD-patients referred to
the department of neurophysiology at Akershus univer-
sity hospital, even though the high prevalence of sleep
problems in this patient group is widely accepted.
In the group-wise regression model, only three factors
were significantly associated with PDSS score, namely
poor mental health, restless legs syndrome, and fatigue.
Our finding that mental health problems strongly pre-
dicted sleep problems in PD patients was not surprising.
The close relationship between the two is well known,
both in the general population [30] and in patients with
PD [31,32]. Although the direction of causality between
them is often difficult to establish, a large population-
based longitudinal study recently showed that both in-
somnia and depression strongly and similarly predicted
the onset of the other [33]. In PD, however, the extent of
these associations and how they relate to the clinicalheterogeneity in PD is not fully understood, and there is
therefore a need for longitudinal studies to examine the
nature of the entwined relationship between sleep pro-
blems and depression in this patient group.
In the current study, sleep problems as measured by
the PDSS, was significantly associated with fatigue,
which is in accordance with other studies [34]. In con-
trast, studies assessing daytime somnolence (such as the
Epworth Sleepiness Scale) rather than nocturnal pro-
blems, generally do not find such an association [35,36].
As fatigue is an undifferentiated problem present in the
general population and associated with several somatic
complaints, the entwined relationship between sleep
problems and fatigue needs to be elucidated.
In this study, the prevalence of RLS was 27% and an
association was found with sleep problems. Few have
examined this association in PD patients, and previous
results are contradictory. However, those using a disease
specific sleep scale, such as SCOPA-Sleep or PDSS re-
port an association [37,38], while those finding no asso-
ciation tended to use generic sleep assessment scales,
such as the Epworth Sleepiness Scale or the Pittsburgh
Sleep Quality Index [15,39]. The PDSS has one item on
nocturnal restlessness (item 4), and as in other studies
those with RLS have significantly lower score on this
item [22]. The relationship between PDSS and RLS is
still significant when item4 is removed from the analysis
(data not shown). In line with earlier suggestions, the
PDSS can be helpful in identifying RLS symptoms in PD
patients.
An interesting and surprising finding was that stage of
disease, measured by both Hoehn and Yahr and UPDRS
sum part III separately, was not associated with PDSS
score in this population. This finding is in disagreement
with other studies examining the association between
sleep problems and PD severity [9,22]. However, in this
community-based study of medicated patients, 71% had
a mild disease. We would have expected that patients
with severe PD-symptoms also reported more sleep pro-
blems than patients with less severe PD. It should be
noted that the current study did not include the most
severe PD patients (Hoehn and Yahr stage 5), and as
such, it might be that sleep problems are more prevalent
among the most severely affected PD patients.Conclusion
The current findings call for increased awareness of
sleep problems in PD patients, especially focusing on the
association with mental health problems, fatigue and
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